---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002072"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:24:44.090104+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Replimune reports ~$466M cash, runway into 2H 2026; updates RP1/RP2 clinical data

## Summary
- Preliminary cash and equivalents of ~$466M as of Dec 31, 2023; funds operations into second half of 2026.
- Updated clinical data for RP1 and RP2 presented at 42nd J.P. Morgan Healthcare Conference.
- Cash estimate is unaudited, subject to completion of quarterly closing procedures.

## SEC filing metadata
- accession: 0001104659-24-002072
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924002072/0001104659-24-002072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924002072/tm242298d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002072
- JSON: https://secwatch.observer/filing/0001104659-24-002072.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.